LIVE
BIIB
Biogen Inc. · Healthcare
$196.58
+3.16% this month
VERSUS
⟷
COMPARE
REGN
Regeneron Pharmaceuticals, Inc. · Healthcare
$609.94
-3.23% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BIIB
2
REGN
3
Comparison scoreboard
REGN LEADS 3/5AI Score
BIIB 28.5
REGN ✓42.1
1Y Return
BIIB ✓+55.33%
REGN +19.86%
Fwd P/E
BIIB 11.99
REGN ✓11.38
Target Up.
BIIB +10.29%
REGN ✓+36.13%
Op. Margin
BIIB ✓22.90%
REGN 20.66%
Metrics last refreshed: 6/20/2026
Quick take
BIIB vs REGN Stock Comparison: AI Score, Valuation, Performance and Upside
Biogen and Regeneron are both large biotechs but at very different points in their commercial development. Regeneron has multiple commercial blockbusters (Dupixent, EYLEA, Libtayo) with strong and growing revenue. Biogen is in transformation — declining MS revenue while attempting to build Leqembi Alzheimer's as the next revenue driver. Regeneron's diversified commercial portfolio is far stronger than Biogen's transition-dependent positioning.
BIIB vs REGN is the Alzheimer's drug pioneer in revenue transformation as MS drugs decline and Leqembi commercial ramp builds (Biogen) versus the multiple-blockbuster biotech with Dupixent growing $14B+ and proprietary VelociSuite pipeline (Regeneron) — commercial transition risk vs diversified blockbuster compounding.
Live analysis · updated 6/20/2026
REGN holds the edge across 3 of 5 key metrics in this comparison. BIIB has delivered stronger 1-year price return (+55.33% vs +19.86%), though REGN trades at the lower forward P/E (11.38x vs 11.99x). On fundamentals, REGN is growing revenue faster (19.00%), while BIIB maintains the higher operating margin (22.90%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for REGN (+36.13%) than for BIIB (+10.29%).
Normalized 1Y performance
BIIB
REGN
Recent returns
BIIB
REGN
Analyst price targets & sentiment
BIIB · 31 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.2/5.0)
Price target range
analyst low$115.00
analyst high$260.00
analyst mean$220.63
current price$196.58
+10.3% upside to analyst mean
REGN · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$535.00
analyst high$950.00
analyst mean$833.31
current price$609.94
+36.1% upside to analyst mean
Who should consider this stock?
BIIB may suit investors who:
- →prefer Alzheimer's disease drug pioneer exposure with Leqembi as the first disease-modifying Alzheimer's treatment beginning commercial launch
- →value Biogen as a potential recovery story if Leqembi commercial adoption accelerates as Alzheimer's diagnostic pathways improve
- →want speculative biotech exposure to the Alzheimer's market — potentially the largest neurology drug opportunity if treatment becomes mainstream
- →are comfortable with slow Leqembi commercial ramp, MS drug revenue decline, Lilly Kisunla Alzheimer's competition, and ARIA side effect monitoring requirements slowing adoption
REGN may suit investors who:
- →prefer the fully diversified independent biotech with Dupixent's blockbuster growth, EYLEA franchise, and Libtayo oncology providing multiple simultaneous revenue drivers
- →value Regeneron's VelociSuite internal pipeline generating new drug candidates without partnership dependency
- →want the highest-quality independent large biotech compounding with Dupixent still mid-growth trajectory and additional indication approvals ahead
- →are comfortable with EYLEA biosimilar transition risk, Dupixent competition in atopic dermatitis, and atypically high valuation for a company without primary R&D pipeline risk
Performance & AI score
| Metric | BIIB | REGN |
|---|---|---|
| AI score | 28.5 | 42.1 |
| AI rank | #2417 | #882 |
| Latest close | $196.58 | $609.94 |
| 1M return | +3.16% | -3.23% |
| 6M return | +14.22% | -18.65% |
| 1Y return | +55.33% | +19.86% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BIIB | REGN |
|---|---|---|
| 1Y ago | $15.54K (+55.4%) started 2025-06-18 | $11.88K (+18.8%) started 2025-06-18 |
| 5Y ago | $5.16K (-48.4%) started 2021-06-21 | $11.46K (+14.6%) started 2021-06-21 |
| 10Y ago | $8.28K (-17.2%) started 2016-06-20 | $17.37K (+73.7%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BIIB | REGN |
|---|---|---|
| Market cap | $29.53B | $64.18B |
| Trailing P/E | 21.51 | 14.95 |
| Forward P/E | 11.99 | 11.38 |
| Price/Sales | 1.99 | 3.78 |
| EV/Revenue | 3.20 | 3.77 |
| Analyst target | $220.63 | $833.31 |
| Target upside | +10.29% | +36.13% |
Growth, profitability & risk
| Metric | BIIB | REGN |
|---|---|---|
| Revenue growth | 1.90% | 19.00% |
| Earnings growth | 31.10% | -7.20% |
| EPS growth | +31.10% | -7.20% |
| FCF margin | +19.43% | +21.94% |
| Operating margin | 22.90% | 20.66% |
| Profit margin | 13.80% | 29.65% |
| ROIC proxy | 7.70% | 14.55% |
| Return on equity | 7.70% | 14.55% |
| Dividend yield | N/A | 0.61% |
| Beta | 0.18 | 0.24 |
| Debt/equity | 35.18 | 8.61 |
| Current ratio | 3.06 | 3.56 |
| Quick ratio | 2.02 | 2.84 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BIIB max drawdown14.34%
REGN max drawdown26.05%
BIIB max wkly drop12.37%
REGN max wkly drop12.87%
5Y risk snapshot
BIIB max drawdown70.23%
REGN max drawdown59.69%
BIIB max wkly drop13.62%
REGN max wkly drop20.21%
10Y risk snapshot
BIIB max drawdown72.66%
REGN max drawdown59.69%
BIIB max wkly drop34.30%
REGN max wkly drop20.21%
Performance metrics by period
| Period | Metric | BIIB | REGN |
|---|---|---|---|
| 1Y | Growth | +55.35% | +18.76% |
| CAGR | +55.45% | +18.79% | |
| Sharpe ratio | 1.36 | 0.55 | |
| Max drawdown | 14.34% | 26.05% | |
| Max daily drop | 6.43% | 9.82% | |
| Max wkly drop | 12.37% | 12.87% | |
| 5Y | Growth | -48.39% | +14.48% |
| CAGR | -12.41% | +2.75% | |
| Sharpe ratio | -0.36 | 0.10 | |
| Max drawdown | 70.23% | 59.69% | |
| Max daily drop | 7.39% | 19.01% | |
| Max wkly drop | 13.62% | 20.21% | |
| 10Y | Growth | -17.19% | +73.43% |
| CAGR | -1.87% | +5.66% | |
| Sharpe ratio | 0.04 | 0.19 | |
| Max drawdown | 72.66% | 59.69% | |
| Max daily drop | 29.23% | 19.01% | |
| Max wkly drop | 34.30% | 20.21% |
Business comparison
| Category | BIIB | REGN |
|---|---|---|
| Company | Biogen Inc. | Regeneron Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | Biogen is a biopharmaceutical company historically known for multiple sclerosis drugs (Tecfidera, Tysabri, Avonex) but now pivoting to Alzheimer's disease with Leqembi (lecanemab — with Eisai) and Skyclarys (omaveloxolone for Friedreich's ataxia). Biogen's MS drug portfolio is declining due to generic Tecfidera erosion and oral MS drugs. Leqembi (anti-amyloid antibody) is the first Alzheimer's drug showing statistically significant slowing of cognitive decline in patients with early symptomatic Alzheimer's. | Regeneron is one of the most exceptional independent biotechs, driven by Dupixent (dupilumab — IL-4/IL-13 biologic for atopic dermatitis, asthma, COPD, and more) as a blockbuster with multiple additional indication approvals. EYLEA HD competes with biosimilar EYLEA in AMD. Libtayo is Regeneron's cancer immunotherapy. Regeneron's VelociSuite antibody discovery platform generates a deep pipeline. Unlike Biogen, Regeneron has multiple commercial products with strong revenues. |
| Investor focus | Investors track Leqembi US and global commercial launch sales, MS drug portfolio decline rate, Alzheimer's diagnostic infrastructure development (PET scans or blood-based amyloid tests needed before prescribing), and pipeline beyond Leqembi. | Investors track Dupixent's global quarterly sales and new indication approvals, EYLEA HD penetration vs biosimilar competition, Libtayo oncology expansion, and VelociSuite pipeline programs. |
BIIB strengths
- →Leqembi is the first disease-modifying Alzheimer's treatment — addressing the largest unmet medical need in neurology
- →Eisai co-promotion partnership for Leqembi reduces Biogen's marketing cost burden for global commercialization
- →MS franchise provides existing revenue base while Leqembi builds commercial scale — preventing a revenue cliff during the Alzheimer's launch period
REGN strengths
- →Dupixent is one of the highest-revenue growing biologics globally — achieving $14B+ annual sales with additional indication approvals still upcoming in COPD, food allergies, and atopic diseases
- →Multiple commercial products: Dupixent, EYLEA HD, and Libtayo provide diversified revenue beyond dependence on any single drug
- →VelociSuite proprietary technology platform produces high-quality antibody drug candidates faster than conventional methods
Risks to watch — BIIB
- →Leqembi commercial adoption has been slower than hoped — Alzheimer's diagnosis workflow, patient monitoring requirements (MRI for ARIA side effects), and payer coverage complexities slow uptake
- →MS drug revenue is declining as generics erode and new oral MS drugs gain market share
- →Lilly's Kisunla (donanemab) as a competing Alzheimer's drug approval adds competition in the small early Alzheimer's patient pool where both drugs can be prescribed
Risks to watch — REGN
- →EYLEA original formulation faces increasing biosimilar competition — Regeneron must transition patients to EYLEA HD to maintain the franchise
- →Dupixent's patent cliff will eventually require lifecycle management through label extensions and next-generation molecules
- →AbbVie's Rinvoq, Lilly's Lebrikizumab compete in atopic dermatitis against Dupixent
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →